World's first artificial human platelet lysate
BioScience Raises the Bar in Cell Culture Technology with artificial HPL
PL BioScience GmbH, a German life science company specializing in the production and development of Human platelet lysate (HPL) for cell expansion, announced the first-ever production of an artificial HPL cell culture solution. In partnership with the Korean biotech DewCell Biotherapeutics (DewCell), the first company to generate artificial platelets from stem cells in a reactor, PL BioScience has developed a proprietary method to transform these lab-grown platelets into a powerful cell culture supplement. Produced in Germany with raw material from DewCell, this new technology offers a scalable, safe, and animal-free alternative to Fetal Calf/Bovine Serum (FCS/FBS) and donor-derived, natural HPL for regenerative medicine, cell therapy, and biopharma applications. A patent for the process has been filed.
“Cell culture innovation is crucial for advancing modern medicine, drug discovery, and understanding complex biological systems,” said Dr. Hatim Hemeda, Chief Executive Officer of PL BioScience. “We are proud to contribute to the field with the very first, scalable artificial HPL solution that, in the mid-term, can be produced in a nearly unlimited supply to meet the growing biopharmaceutical industry needs.”
“We are confident that the combination of DewCell's innovative technology and our cell culture expertise will usher in a new era in the field of regenerative medicine and cell therapy manufacturing,” he added.
HPL is a safe, high-performance cell culture supplement that can be used as an alternative to FBS/FCS. HPL is manufactured from donated human blood platelets that are outdated and no longer safe for transfusion, making them a sustainable but limited source to produce HPL. With its proprietary technology for the synthetic production of HPL in conjunction with DewCell’s artificial platelet technology, PL BioScience can overcome this limitation and provides a fully scalable, high-performing cell culture supplement for biopharmaceutical applications.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.